Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer

Publikation

Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer

Wissenschaftlicher Artikel/Review - 23.08.2010

du Bois Andreas, Jelic Svetislav, Pujade-Lauraine Eric, Burges Alexander, Pfisterer Jacobus, Gropp Martina, Staehle Anne, Wimberger Pauline, Jackisch Christian, Kurzeder Christian, Weber Béatrice, Herrstedt Jørn, Hardy-Bessard Anne-Claire, Müller Hans-Helge, Harter Philipp, Kristensen Gunnar, Joly Florence, Huober Jens, Avall-Lundqvist Elisabeth, Sehouli Jalid

Zitation

du Bois A, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Kurzeder C, Weber B, Herrstedt J, Hardy-Bessard A, Müller H, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28:4162-9.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Clin Oncol 2010; 28

Veröffentlichungsdatum

23.08.2010

eISSN (Online)

1527-7755

Seiten

4162-9

Kurzbeschreibung/Zielsetzung

One attempt to improve long-term survival in patients with advanced ovarian cancer was thought to be the addition of more non-cross-resistant drugs to platinum-paclitaxel combination regimens. Gemcitabine was among the candidates for a third drug.